breakout

Key Highlights NZD/USD is attempting a fresh increase above the 0.6000 resistance zone. It broke a major bearish trend line with resistance at 0.5990 on the 4-hour chart. Gold prices remain elevated ahead of…

's consolidation phase has entered its fourth week amid a bearish outlook. However, certain technical indicators suggest that the negative sentiment surrounding the crypto might shift soon. Recently, market sentiment has been…

Big week for minor currency pair BoC + ECB rate decisions in focus EURCAD trapped within 300 pip range Prices gaining bullish momentum on D1   Bloomberg model: 76% chance EURCAD – (1.45454 – 1.48439) Key central bank…

EURAUD waits for directional spark Prices rangebound on M1 chart Incoming data could rock minor currency pair Technical indicators favour bulls Bloomberg model: 77% chance EURAUD – (1.64508 – 1.67710) Were you able to catch your…

(Kitco News) - The gold market continues to consolidate after hitting record highs, and while the price has room to fall further, one market strategist said that the precious metal is ultimately headed higher.In his latest market…

USD/JPY OUTLOOKHigher-than-expected U.S. inflation numbers propel U.S. Treasury yields higher, boosting the U.S. dollar across the boardUSD/JPY soars past the 150.00 mark, hitting its highest level in nearly three monthsThis article…

Bitcoin eyes bullish breakout to 45,000 amid ETF inflows and risk-on sentiment. Bearish view: sell-stop at 43,000, target 42,000. Fed's rate stance and upcoming halving event key influencers. Watch 43,720 resistance.Buy the BTC/USD and…

For an extensive analysis of gold’s medium-term prospects, which incorporate insights from fundamental and technical viewpoints, download the Q1 trading forecast now! Recommended by Diego Colman Get Your Free…

TL;DR Bitcoin (BTC): Reached over $44,000 in December but then declined. Analysts predict potential rise to $100,000 by 2025-2026, influenced by the 2024 halving event. Ripple (XRP): Peaked above $0.80 in July,…

Teva stock made inroads toward its 50-day line on Wednesday after the pharma giant rode its generics drugs business to a third-quarter beat. X During the September quarter, Teva Pharmaceutical's (TEVA) generic drugs division…